Page 15 - Read Online
P. 15

Feun et al.                                                                                                                                                               Immunotherapy for hepatocellular carcinoma

               Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH,   evidence and potential for improving overall survival. Clin Cancer
               Carson WE 3rd. The Raf kinase inhibitor sorafenib inhibits JAK-  Res 2012;18:3686-96.
               STAT signal transduction in human immune cells. J Immunol   52.  Zhu AX, Gold PJ, El-Koueiry AB, Abrams TA, Morikawa H,
               2015;195:1995-2005.                               Ohtomo T, Philip PA. A phase I study of GC33, a recombinant
           45.  Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, Yang PC, Cheng   humanized antibody against glypican-3, in patients with advanced
               AL. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibtions   hepatocellular carcinoma (HCC). J Clin Oncol 2011;29 suppl:abstr
               of effector T cells in tumor environment to augment antitumor   4085.
               immunity. Int J Cancer 2014;134:319-31.        53.  Okusaka T, Ikeda M, Ohkawa S, Yamamoto S, Suzuki I, Furuse J. A
           46.  Chen J, Ji T, Zhao J, Li G, Zhang J, Jin R, Liu J, Liu X, Liang   phase I study of GC33 in Japanese patients with advanced hepatocellular
               X, Huang D, Xie A, Lin H, Cang Y, Cai X. Sorafenib-resistant   carcinoma (HCC). J Clin Oncol 2013;31 suppl 4:abstr 235.
               hepatocellular carcinoma stratified by phosphorylated ERK activates   54.  Abou-Alfa GK, Yen CJ, Carrasquillo JA, Hsu CH, Gansukh B, Ma
               PD-1 immune checkpoint. Oncotarget 2016;7:41274-84.  J, Hollywood E, Wan PJ, Shao YY, Lin ZZ, Frenette C, O’Neil BH,
           47.  Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C,   Schwartz LH, Ohtomo T, Tanaka T, Chen YC, Ukrainskyj S, Saltz
               Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, Lafdil   L, Lee RM, Cheng AL. Phase I b study of RO5137382/GC33 in
               F, Pawlotsky JM. Programmed death ligand 1 expression in   combination with sorafenib in patients with advanced hepatocellular
               hepatocellular carcinoma: relationship with clinical and pathological   carcinoma (HCC) (NCT00976170). J Clin Oncol 2014;32 suppl:abstr
               features. Hepatology 2016;64:2038-46.             4100.
           48.  Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E,   55.  Hashimoto K, Perera A, Ogita Y, Nakamura M, Ishiguro T, Sano Y,
               Filmus J. Glypican-3: a novel serum and histochemical marker for   Kinoshita Y, Sakurai MK, Frings W, Komatsu SI, Kaneko A, Ueda
               hepatocellular carcinoma. Gastroenterology 2003;125:89-97.  M, Kishishita S, Gianella-Borradori A. A phase I dose escalation
           49.  Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target   and cohort expansion study of T-cell redirecting bispecific antibody
               in hepatocellular carcinoma. FEBS J 2013;280:2471-6.  against Glypican 3 in patients with advanced solid tumors. J Clin
           50.  Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the   Oncol 2016;34 suppl:abstr TPS2592.
               growth of hepatocellular carcinoma by stimulating canonical Wnt   56.  Donkor MK, Sarkar A, Li MO. TGF-β1 produced by activated
               signaling. Cancer Res 2005;65:6245-54.            CD4(+) T cells antagonized T cell surveillance of tumor development.
           51.  Sawada Y, Yoshikawa T, Nobucka D, Shirakawa H, Kuronuma T,   Oncoimmunology 2012;1:162-71.
               Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T,   57.  Song S, Yuan P, Wu H, Chen J, Fu J, Li P, Lu J, Wei W. Dendritic
               Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse   cells with an increased PD-L1 by TGF-β induce T cell anergy for the
               J, Kinoshita T, Nakatsura T. Phase I trial of a glypican-3-derived   cytotoxicity of hepatocellular carcinoma cells. Int Immunopharmacol
               peptide vaccine for advanced hepatocellular carcinoma: immunologic   2014;20:117-23.












































                           Hepatoma Research ¦ Volume 3 ¦ March 22, 2017                                   51
   10   11   12   13   14   15   16   17   18   19   20